Will new antischistosomal drugs finally emerge?

Trends in Parasitology

Volumn 24, Issue 9, 2008, Pages 379-382

  Cioli, Donato ^a   Valle, Cristiana ^a   Angelucci, Francesco ^b   Miele, Adriana E ^b  

^a CNR   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY TARTRATE; ANTISCHISTOSOMAL AGENT; ARTEMISININ; AURANOFIN; FURAZOLIDONE; GLUTAREDOXIN; GLUTATHIONE; GLUTATHIONE REDUCTASE; OLTIPRAZ; OXADIAZOLE 2 OXIDE; OXADIAZOLE DERIVATIVE; PHOSPHINE DERIVATIVE; PHOSPHINIC AMIDE; PRAZIQUANTEL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIOREDOXIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; CARBOXY TERMINAL SEQUENCE; COST OF ILLNESS; CRYSTAL STRUCTURE; DETOXIFICATION; DEVELOPMENTAL STAGE; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ECHINOCOCCUS; ECHINOCOCCUS GRANULOSUS; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; IC 50; IN VITRO STUDY; INFECTION PREVENTION; LONG TERM CARE; MAMMAL CELL; MORBIDITY; NONHUMAN; OXIDATION REDUCTION REACTION; RNA INTERFERENCE; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SHORT SURVEY; TAENIA; TAENIA CRASSICEPS; TOXICITY TESTING; TREATMENT DURATION;

ANIMALS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE; GLUTATHIONE; HUMANS; MULTIENZYME COMPLEXES; NADH, NADPH OXIDOREDUCTASES; OXIDATION-REDUCTION; SCHISTOSOMA; SCHISTOSOMIASIS; SCHISTOSOMICIDES; THIOREDOXINS;

EID: 49449093529     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2008.05.006     Document Type: Short Survey

References (24)

1. Van der Werf M.J., et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 86 (2003) 125-140
2. Savioli L., et al. Progress in the prevention and control of schistosomiasis and soil-transmitted helminthiasis. Parasitol. Int. 53 (2004) 103-113
3. Hotez P., et al. Recent progress in integrated neglected tropical disease control. Trends Parasitol. 23 (2007) 511-514
4. King C.H., et al. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365 (2005) 1561-1569
5. Finkelstein J.L., et al. Decision-model estimation of the age-specific disability weight for schistosomiasis japonica: a systematic review of the literature. PLoS Negl. Trop. Dis. 2 (2008) e158
6. Cioli D., et al. Antischistosomal drugs: past, present... and future?. Pharmacol. Ther. 68 (1995) 35-85
7. Utzinger J., et al. The potential of artemether for the control of schistosomiasis. Int. J. Parasitol. 31 (2001) 1549-1562
8. Sayed A.A., et al. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat. Med. 14 (2008) 407-412
9. Williams D.L., et al. Molecular cloning and sequencing of glutathione peroxidase from Schistosoma mansoni. Mol. Biochem. Parasitol. 52 (1992) 127-130
10. Roche C., et al. Cloning and characterization of the gene encoding Schistosoma mansoni glutathione peroxidase. Gene 138 (1994) 149-152
11. Alger H.M., et al. Molecular and enzymatic characterisation of Schistosoma mansoni thioredoxin. Int. J. Parasitol. 32 (2002) 1285-1289
12. Alger H.M., and Williams D.L. The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Mol. Biochem. Parasitol. 121 (2002) 129-139
13. Sayed A.A., et al. Redox balance mechanisms in Schistosoma mansoni rely on peroxiredoxins and albumin and implicate peroxiredoxins as novel drug targets. J. Biol. Chem. 281 (2006) 17001-17010
14. Sayed A.A., et al. Biochemical characterization of 2-Cys peroxiredoxins from Schistosoma mansoni. J. Biol. Chem. 279 (2004) 26159-26166
15. Salinas G., et al. Linked thioredoxin-glutathione systems in platyhelminths. Trends Parasitol. 20 (2004) 340-346
16. Sun Q.A., et al. Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3673-3678
17. Agorio A., et al. Alternative mRNAs arising from trans-splicing code for mitochondrial and cytosolic variants of Echinococcus granulosus thioredoxin glutathione reductase. J. Biol. Chem. 278 (2003) 12920-12928
18. Rendón J.L., et al. Purification, characterization and kinetic properties of the multifunctional thioredoxin-glutathione reductase from Taenia crassiceps metacestode (cysticerci). Mol. Biochem. Parasitol. 133 (2004) 61-69
19. Kuntz A.N., et al. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 4 (2007) e206
20. Simeonov A., et al. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl. Trop. Dis. 2 (2008) e127
21. James S.L., and Glaven J. Macrophage cytotoxicity against schistosomula of Schistosoma mansoni involves arginine-dependent production of reactive nitrogen intermediates. J. Immunol. 143 (1989) 4208-4212
22. Cerecetto H., and Porcal W. Pharmacological properties of furoxans and benzofuroxans: recent developments. Mini Rev. Med. Chem. 5 (2005) 57-71
23. Angelucci F., et al. Glutathione reductase and thioredoxin reductase at the crossroads: the structure of Schistosoma mansoni thioredoxin glutathione reductase. Proteins 72 (2008) 936-945
24. Brown D., and Superti-Furga G. Rediscovering the sweet spot in drug discovery. Drug Discov. Today 8 (2003) 1067-1077